The Clinical Impact and Cost-Effectiveness of Clinic-Based Cognitive Behavioral Therapy for People With HIV, Depression, and Virologic Failure in South Africa.

Journal: Journal of acquired immune deficiency syndromes (1999)

Volume: 93

Issue: 4

Year of Publication: 2023

Affiliated Institutions:  Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA. Harvard Medical School, Boston, MA. HIV Mental Health Research Unit, Department of Psychiatry, University of Cape Town, Cape Town, South Africa. Global Health Section, Department of Public Health, University of Copenhagen, Copenhagen, Denmark; and. Department of Psychology, University of Miami, Miami, FL.

Abstract summary 

Depression affects 25%-30% of people with HIV (PWH) in the Republic of South Africa (RSA) and is associated with both antiretroviral therapy (ART) nonadherence and increased mortality. We evaluated the cost-effectiveness of task-shifted, cognitive behavioral therapy (CBT) for PWH with diagnosed depression and virologic failure from a randomized trial in RSA.RSA.Using the Cost-Effectiveness of Preventing AIDS Complications model, we simulated both trial strategies: enhanced treatment as usual (ETAU) and ETAU plus CBT for ART adherence and depression (CBT-AD; 8 sessions plus 2 follow-ups). In the trial, viral suppression at 1 year was 20% with ETAU and 32% with CBT-AD. Model inputs included mean initial age (39 years) and CD4 count (214/μL), ART costs ($7.5-22/mo), and CBT costs ($29/session). We projected 5- and 10-year viral suppression, quality-adjusted life-years (QALYs), lifetime costs, and incremental cost-effectiveness ratios (ICERs: $/QALY [discounted 3%/yr]; cost-effectiveness threshold: ≤$2545/QALY [0.5× per capita GDP]). In sensitivity analyses, we determined how input parameter variation affected cost-effectiveness.Model-projected 5- and 10-year viral suppression were 18.9% and 8.7% with ETAU and 21.2% and 9.7% with CBT-AD, respectively. Compared with ETAU, CBT-AD would increase discounted life expectancy from 4.12 to 4.68 QALYs and costs from $6210/person to $6670/person (incremental cost-effectiveness ratio: $840/QALY). CBT-AD would remain cost-effective unless CBT-AD cost >$70/session and simultaneously improved 1-year viral suppression by ≤4% compared with ETAU.CBT for PWH with depression and virologic failure in RSA could improve life expectancy and be cost-effective. Such targeted mental health interventions should be integrated into HIV care.

Authors & Co-authors:  Gandhi Aditya R AR Hyle Emily P EP Scott Justine A JA Lee Jasper S JS Shebl Fatma M FM Joska John A JA Andersen Lena S LS O'Cleirigh Conall C Safren Steven A SA Freedberg Kenneth A KA

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Joint United Nations Programme on HIV/AIDS. UNAIDS Data. 2020. Available from: https://www.unaids.org/en/resources/documents/2020/unaids-data. Accessed February 24, 2022.
Authors :  10
Identifiers
Doi : 10.1097/QAI.0000000000003205
SSN : 1944-7884
Study Population
Male,Female
Mesh Terms
Humans
Other Terms
Study Design
Randomized Control Trial,Cross Sectional Study
Study Approach
Country of Study
South Africa
Publication Country
United States